Therapeutic Target Details
| Target ID: | T20 |
| Target Name: | Fatty acid synthase |
| Synonyms: | FAS; FASN |
| GENE: | FASN |
| Action: | inhibitor |
| Class: | Enzyme |
| UniProtKB ID: | P49327 |
| Entry Name: | FAS_HUMAN |
| Related Drugs: | TVB-2640 |
| Mechanism: | Fatty acid synthase (FAS) is a critical enzyme in the DNL pathway that uses malonyl-CoA, synthesized by ACC, to form saturated long-chain fatty acids. The hepatic expression and activity of FAS are upregulated in NAFLD and preclinical studies in obese mice demonstrate that FAS inhibition lowers liver levels of triglycerides and improves insulin sensitivity. |
| Reference (PMIDs): | 21389266 |
| Compound ID | Source ID | Source Type | Compound Name | Molecular Weight | Molecular Formula | Molecular Species | |
|---|---|---|---|---|---|---|---|
| B000787 | CHEMBL1090448 | Small molecule | -- | 414.32 | C20H14O10 | NEUTRAL | Details |
| B000963 | CHEMBL1093743 | Small molecule | -- | 280.45 | C18H32O2 | ACID | Details |
| B001920 | CHEMBL1219 | Small molecule | RABEPRAZOLE | 359.45 | C18H21N3O3S | NEUTRAL | Details |
| B002077 | CHEMBL1224332 | Small molecule | CUDRAXANTHONE | 326.35 | C19H18O5 | NEUTRAL | Details |
| B002155 | CHEMBL1235157 | Small molecule | PENTABROMOPHENOL | 488.59 | C6HBr5O | ACID | Details |
| B002344 | CHEMBL1255589 | Small molecule | LORGLUMIDE SODIUM | 481.4 | C22H31Cl2N2NaO4 | ACID | Details |
| B002345 | CHEMBL1255647 | Small molecule | -- | 276.12 | C9H2N4Na2O4 | NEUTRAL | Details |
| B002373 | CHEMBL1256379 | Small molecule | -- | 246.22 | C13H10O5 | NEUTRAL | Details |
| B002374 | CHEMBL1256380 | Small molecule | -- | 262.22 | C13H10O6 | NEUTRAL | Details |
| B002443 | CHEMBL1257642 | Small molecule | NEOSMITILBIN | 450.4 | C21H22O11 | NEUTRAL | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00006 | 35256934 | Acta Pharm Sin B | Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma. | Details |
| A00205 | 35187676 | J Food Biochem | Chitosan oligosaccharide attenuates hepatic steatosis in HepG2 cells via the activation of AMP-activated protein kinase. | Details |
| A00213 | 35182670 | J Ethnopharmacol | Gryllus bimaculatus De Geer hydrolysates alleviate lipid accumulation, inflammation, and endoplasmic reticulum stress in palmitic acid-treated human hepatoma G2 cells. | Details |
| A00538 | 35052685 | Biomedicines | Fatty Acid Synthase Inhibitor Platensimycin Intervenes the Development of Nonalcoholic Fatty Liver Disease in a Mouse Model. | Details |
| A00539 | 35052640 | Antioxidants (Basel) | Phytochemicals from the Cocoa Shell Modulate Mitochondrial Function, Lipid and Glucose Metabolism in Hepatocytes via Activation of FGF21/ERK, AKT, and mTOR Pathways. | Details |
| A00540 | 35052597 | Antioxidants (Basel) | Gallic Acid Improves Diabetic Steatosis by Downregulating MicroRNA-34a-5p through Targeting NFE2L2 Expression in High-Fat Diet-Fed db/db Mice. | Details |
| A00658 | 35013040 | J Oleo Sci | Pink Lotus Essential Oil and Alleviates on Free Fatty Acid Induced Steatosis in HepG2 Cells via PI3K/Akt and NF-κB Pathways. | Details |
| A00748 | 34981123 | Biosci Rep | Tandem mass tag-based proteomics analysis of type 2 diabetes mellitus with non-alcoholic fatty liver disease in mice treated with acupuncture. | Details |
| A01056 | 34884968 | Int J Mol Sci | Neochlorogenic Acid Attenuates Hepatic Lipid Accumulation and Inflammation via Regulating miR-34a In Vitro. | Details |
| A01219 | 34825068 | Biochem Biophys Rep | Metformin treatment reverses high fat diet- induced non-alcoholic fatty liver diseases and dyslipidemia by stimulating multiple antioxidant and anti-inflammatory pathways. | Details |
| A01357 | 34776827 | Food Nutr Res | Weissella cibaria MG5285 and Lactobacillus reuteri MG5149 attenuated fat accumulation in adipose and hepatic steatosis in high-fat diet-induced C57BL/6J obese mice. | Details |
| A01411 | 34757160 | Toxicology | The combined impact of decabromodiphenyl ether and high fat exposure on non-alcoholic fatty liver disease in vivo and in vitro. | Details |
| A01542 | 34704008 | Metabol Open | Deficiency of SREBP1c modulates autophagy mediated lipid droplet catabolism during oleic acid induced steatosis. | Details |
| A01652 | 34667947 | JHEP Rep | New targets for NAFLD. | Details |
| A01693 | 34652536 | Mol Cell Biochem | Acetylation of H3K27 activated lncRNA NEAT1 and promoted hepatic lipid accumulation in non-alcoholic fatty liver disease via regulating miR-212-5p/GRIA3. | Details |
| A01698 | 34651285 | J Physiol Biochem | Astaxanthin attenuates hepatic steatosis in high-fat diet-fed rats by suppressing microRNA-21 via transactivation of nuclear factor erythroid 2-related factor 2. | Details |
| A01775 | 34621326 | Evid Based Complement Alternat Med | A Novel Identified Peptide Hormone "Metabolitin" Attenuates Lipid Absorption in the Small Intestine of Diabetic Mice with Nonalcoholic Fatty Liver Disease by Regulating Neurotensin and AMPK Signaling Pathway. | Details |
| A01777 | 34621168 | Front Pharmacol | Study on the Hepatoprotection of Schisandra chinensis Caulis Polysaccharides in Nonalcoholic Fatty Liver Disease in Rats Based on Metabolomics. | Details |
| A01861 | 34585409 | J Food Biochem | Crataegus aronia prevents high-fat diet-induced hepatic steatosis in rats by activating AMPK-induced suppression of SREBP1 and activation of PPARα. | Details |
| A01875 | 34576229 | Int J Mol Sci | Methyl Brevifolincarboxylate Attenuates Free Fatty Acid-Induced Lipid Metabolism and Inflammation in Hepatocytes through AMPK/NF-κB Signaling Pathway. | Details |